Evaluate

Evaluate is a commercial-intelligence provider for the pharmaceutical, biotechnology, and medical-technology sectors. It supplies drug-sales histories and forecasts, pipeline and clinical-event tracking, epidemiology, deal information, competitive intelligence, forecasting software, data feeds, and consulting services.^[1] Evaluate operates as a brand of the life-sciences information group Norstella.^[3][5].

Evaluate Pharma is the company's principal market-forecasting product and is presented as a source of consensus forecasts for pharmaceutical firms, investment banks, and consultancies.^[1][2] Independent evidence of external use appears in PubMed: indexed research has used EvaluatePharma forecasts to compare expected drug sales, and other papers have cited its World Preview reports.^[4]

What It Does

Evaluate organizes information about the commercial development of medicines and medical products. Its documented workflows include market sizing, long-range forecasting, portfolio and asset strategy, business development and licensing, competitive monitoring, and investment analysis.^[1] The information is intended to support decisions about markets and assets; it is not a source of clinical advice for patients.^[1]

The company supplements structured products with research reports, webinars, disease reports, and consulting. Norstella describes Evaluate's role as collecting, calibrating, and connecting pharmaceutical information, with tailored expertise available alongside the data.^[3]

Data and Methodology

Evaluate Pharma combines reported sales with consensus forecasts, meaning estimates assembled from contributing market analysts rather than a single proprietary prediction.^[1][2] Evaluate Omnium applies machine-learning methods across data concerning the clinical pipeline, including early-stage and privately held assets, while Evaluate Epi provides epidemiological context for commercial assessment.^[1]

Related products track development events, regulatory catalysts, transactions, scientific literature, medical-device filings, and regional forecasts.^[1] Forecasts remain estimates and can change as trials, approvals, competition, pricing, and analyst assumptions change. The PubMed record confirms that researchers have compared EvaluatePharma data with other commercial sources rather than treating it as the sole benchmark.^[4]

Products

The portfolio includes Evaluate Pharma for sales and consensus forecasts; Evaluate Omnium for pipeline analysis; Evaluate Epi for epidemiology; Biomedtracker for events, catalysts, and deals; Datamonitor Healthcare for market analysis; Meddevicetracker for medical-device development; BioSciDB for scientific and pipeline intelligence; and regional drug forecasts for Europe and Japan.^[1][2]

Other offerings include real-world data, CDMO intelligence, data feeds, competitive-intelligence services, forecasting software and training, and custom model development.^[1] Ask Ella is an assistant embedded in Evaluate products that returns sourced answers based on the relevant product's data, while Norstella Atlas CI is presented as an agent for producing sourced competitive-intelligence deliverables.^[1]

Delivery and Pricing

Evaluate provides web-based product logins, enterprise data feeds, reports, software, training, and consulting engagements.^[1] Public pages direct prospective customers to request information or a demonstration and do not display standardized subscription prices.^[1][2] Product scope therefore depends on the contracted modules and delivery arrangement.

Norstella states that Evaluate acquired J+D Forecasting in 2024, adding tools and services for custom and integrated forecasting models across the product life cycle.^[3] The parent-company description is evidence of ownership and product integration, but it is not an independent assessment of forecast accuracy.^[3]

Buyers and Use Cases

Evaluate addresses biopharma companies, professional-services firms, and financial institutions.^[1] Documented uses include market models, portfolio prioritization, licensing analysis, asset valuation, competitor and catalyst monitoring, launch planning, and diligence for mergers, acquisitions, initial public offerings, and private investments.^[1][2]

Academic use is narrower but independently observable. PubMed lists a 2021 review that compared forecast sales using EvaluatePharma, Cortellis, and Nature Biobusiness Briefs, as well as papers citing EvaluatePharma's World Preview material.^[4] This shows that the product has served as a research input; it does not independently validate every forecast or current product claim.^[4]